Retail demand and fiscal calendar

Food retail: C$14,048m; comparable sales +0.6%.

Pharmacy and healthcare: C$3,202m; comparable sales +7.6%.

Front store: C$2,607m; comparable sales +1.6%.

FY2025 additional trading week: C$1,138m of revenue.

Peralta factual exhibit. Original publisher pages are linked in the report.

Q3 report, physical page 12; FY2025 annual report, physical page 32.

Recurring earnings and cash

Quarterly diluted EPS: C$1.03 total, C$0.68 continuing.

40-week continuing operating cash: C$4,716m.

40-week continuing free cash flow: C$1,612m.

40-week dividends paid: C$522m; common repurchases: C$1,721m.

Peralta factual exhibit. Original publisher pages are linked in the report.

Q3 report, physical pages 19, 46, 50.

Capital claims and the common share

Cash: C$1,049m. Equity-accounted investments: C$1,262m.

Borrowings: C$6,103m long term and C$2m bank indebtedness.

Associate interest: C$384m. Minority equity: C$171m.

Quarterly diluted denominator: 1,160.7m shares.

Peralta factual exhibit. Original publisher pages are linked in the report.

Q3 report, physical pages 46, 49 and 58.

Governance and independent comparison

Record-date control: 614,768,382 of 1,168,112,253 common shares.

Loblaw latest quarter: 7.09% operating margin.

Metro latest quarter: 5.96% operating margin.

Empire latest quarter: 4.85% operating margin.

Peralta factual exhibit. Original publisher pages are linked in the report.

2026 circular p. 11; Loblaw Q3 p. 46; Metro Q4 p. 17; Empire Q1 p. 27.